CompletedNCT01655680
ABT-126 for Thinking Difficulties in Schizophrenia
About this title
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
Read the official source — NCT01655680Researchers compared ABT-126 and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.
Medication studyAges 20–65Multiple countries
Understand this study
What did researchers investigate?
Researchers compared ABT-126 and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 20 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Anaheim and 60 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateMay 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 432
- Sponsor
- AbbVie (prior sponsor, Abbott)
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, United Kingdom, Russia
- Age range
- From 20 Years to 65 Years
- Official registry ID
- NCT01655680
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Nonsmokers
Get this study by email
Recruitment & locations
CompletedAnaheim, United States · Bellflower, United States · Chino, United States
46 more locations
- Costa Mesa, United States
- Escondido, United States
- Garden Grove, United States
- La Habra, United States
- National City, United States
- Norwalk, United States
- Oakland, United States
- Oceanside, United States
- Orange, United States
- Pico Rivera, United States
- Riverside, United States
- San Bernardino, United States
- San Diego, United States
- San Gabriel, United States
- Santa Ana, United States
- Torrance, United States
- New Haven, United States
- Atlanta, United States
- Marietta, United States
- Chicago, United States
- Hoffman Estates, United States
- Wichita, United States
- Cedarhurst, United States
- Rochester, United States
- Staten Island, United States
- Philadelphia, United States
- Dallas, United States
- DeSoto, United States
- Houston, United States
- Chita, Russia
- Kazan', Russia
- Lipetsk, Russia
- Moscow, Russia
- Novosibirsk, Russia
- Saint Petersburg, Russia
- Saratov, Russia
- Stavropol, Russia
- Yaroslavl, Russia
- Yekaterinburg, Russia
- Brentford, United Kingdom
- Edinburgh, United Kingdom
- London, United Kingdom
- Newcastle upon Tyne, United Kingdom
- Oxford, United Kingdom
- Preston, United Kingdom
- Russia
Questions about this study
What did researchers investigate?
Researchers compared ABT-126 and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.
Who is behind this study?
The study sponsor is AbbVie (prior sponsor, Abbott).
Did this study involve medication?
Yes. The study involved medication, including ABT-126 and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 20 years to 65 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia